

Analysis Population  
All Participants Randomized

|  | Placebo<br>n (%) | Xanomeline Low<br>Dose<br>n (%) | Xanomeline High<br>Dose<br>n (%) |
|--|------------------|---------------------------------|----------------------------------|
| Participants in population                   | 86               | 84                              | 84                               |
| Participants included in ITT population      | 86 (100.0)       | 84 (100.0)                      | 84 (100.0)                       |
| Participants included in efficacy population | 79 (91.9)        | 81 (96.4)                       | 74 (88.1)                        |
| Participants included in safety population   | 86 (100.0)       | 84 (100.0)                      | 84 (100.0)                       |

Source: ADSL dataset